as well as influencing apoptosis, hsp60 changes in expression level have been shown to be “useful new biomarkers for diagnostic and prognostic purposes.” according to lebret et al., a loss of hsp60 expression “indicates a poor prognosis and the risk of developing tumor infiltration” specifically with bladder carcinomas, but that does not necessarily hold true for other types of cancers. for example, ovarian tumors research has shown that over expression is correlated with a better prognosis while a decreased expression is correlated with an aggressive tumor. all this research indicates that it may be possible for hsp60 expression to be used in predicting survival for certain types of cancer and therefore may be able to identify patients who could benefit from certain treatments.